The company’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over other ...

The loss of muscle mass and strength poses an increasingly significant challenge for an aging society. Prof. Kristina ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...

Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development, manufacture and ...

The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...

Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of new data from ...

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

AnaptysBio (NASDAQ:ANAB – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses ...

The loss of muscle mass and strength poses an increasingly significant challenge for an ageing society. Prof. Kristina Norman's team at the German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE ...